Cerulein hyperstimulation decreases AMP-activated protein kinase levels at the site of maximal zymogen activation

Christina A. Shugrue, Martine Alexandre, Alexander Diaz de Villalvilla, Thomas R. Kolodecik, Lawrence H. Young, Fred S. Gorelick, Edwin C. Thrower

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The premature activation of digestive enzyme zymogens in the pancreatic acinar cell is an important initiating event in acute pancreatitis. We have previously demonstrated that vacuolar ATPase (vATPase) activity is required for zymogen activation. Adenosine monophosphate-activated protein kinase (AMPK) regulates vATPase function in kidney and epididymal clear cells. To determine whether AMPK could affect pancreatitis responses, its effects were first examined in a cellular model of pancreatitis, cerulein-hyperstimulated (100 nM) pancreatic acini. This treatment caused a prominent increase in trypsin and chymotrypsin activities. Pretreatment with AICAR or metformin (AMPK activators) or compound C (an AMPK inhibitor) reduced or increased cerulein-induced zymogen activation, respectively. The association of the vATPase E subunit with membranes, a marker of its activation, tended to be inversely related to AMPK activity (assessed by AICAR and compound C treatments). Cerulein treatment did not change AMPK (- and -) levels but did lead to an increase in its activation (phosphorylation of Thr172) and induced the time-dependent translocation of the enzyme to a Triton-insoluble compartment. Basal in vivo studies showed that AMPK was widely distributed between membrane and soluble fractions generated by differential centrifugation. After cerulein hyperstimulation, AMPK levels selectively decreased in fractions containing the highest levels of active zymogens. These studies suggest that AMPK activity has a protective role in the pancreatic acinar cell that inhibits zymogen activation in the basal state, and this AMPK effect is reduced during pancreatitis. Therapies that prevent the selective reduction of AMPK in compartments that support zymogen activation could reduce injury during pancreatitis.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume303
Issue number6
DOIs
StatePublished - Sep 15 2012
Externally publishedYes

Fingerprint

Ceruletide
Enzyme Precursors
AMP-Activated Protein Kinases
Adenosine Monophosphate
Protein Kinases
Pancreatitis
Vacuolar Proton-Translocating ATPases
Acinar Cells
Enzyme Activation
Membranes
Metformin
Protein Kinase Inhibitors
Centrifugation
Phosphorylation

Keywords

  • Pancreatic acini
  • Vacuolar ATPase

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology (medical)
  • Physiology
  • Hepatology

Cite this

Cerulein hyperstimulation decreases AMP-activated protein kinase levels at the site of maximal zymogen activation. / Shugrue, Christina A.; Alexandre, Martine; de Villalvilla, Alexander Diaz; Kolodecik, Thomas R.; Young, Lawrence H.; Gorelick, Fred S.; Thrower, Edwin C.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 303, No. 6, 15.09.2012.

Research output: Contribution to journalArticle

Shugrue, Christina A. ; Alexandre, Martine ; de Villalvilla, Alexander Diaz ; Kolodecik, Thomas R. ; Young, Lawrence H. ; Gorelick, Fred S. ; Thrower, Edwin C. / Cerulein hyperstimulation decreases AMP-activated protein kinase levels at the site of maximal zymogen activation. In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 2012 ; Vol. 303, No. 6.
@article{26333012627e41e7820501f9213d8eaf,
title = "Cerulein hyperstimulation decreases AMP-activated protein kinase levels at the site of maximal zymogen activation",
abstract = "The premature activation of digestive enzyme zymogens in the pancreatic acinar cell is an important initiating event in acute pancreatitis. We have previously demonstrated that vacuolar ATPase (vATPase) activity is required for zymogen activation. Adenosine monophosphate-activated protein kinase (AMPK) regulates vATPase function in kidney and epididymal clear cells. To determine whether AMPK could affect pancreatitis responses, its effects were first examined in a cellular model of pancreatitis, cerulein-hyperstimulated (100 nM) pancreatic acini. This treatment caused a prominent increase in trypsin and chymotrypsin activities. Pretreatment with AICAR or metformin (AMPK activators) or compound C (an AMPK inhibitor) reduced or increased cerulein-induced zymogen activation, respectively. The association of the vATPase E subunit with membranes, a marker of its activation, tended to be inversely related to AMPK activity (assessed by AICAR and compound C treatments). Cerulein treatment did not change AMPK (- and -) levels but did lead to an increase in its activation (phosphorylation of Thr172) and induced the time-dependent translocation of the enzyme to a Triton-insoluble compartment. Basal in vivo studies showed that AMPK was widely distributed between membrane and soluble fractions generated by differential centrifugation. After cerulein hyperstimulation, AMPK levels selectively decreased in fractions containing the highest levels of active zymogens. These studies suggest that AMPK activity has a protective role in the pancreatic acinar cell that inhibits zymogen activation in the basal state, and this AMPK effect is reduced during pancreatitis. Therapies that prevent the selective reduction of AMPK in compartments that support zymogen activation could reduce injury during pancreatitis.",
keywords = "Pancreatic acini, Vacuolar ATPase",
author = "Shugrue, {Christina A.} and Martine Alexandre and {de Villalvilla}, {Alexander Diaz} and Kolodecik, {Thomas R.} and Young, {Lawrence H.} and Gorelick, {Fred S.} and Thrower, {Edwin C.}",
year = "2012",
month = "9",
day = "15",
doi = "10.1152/ajpgi.00082.2012",
language = "English (US)",
volume = "303",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Cerulein hyperstimulation decreases AMP-activated protein kinase levels at the site of maximal zymogen activation

AU - Shugrue, Christina A.

AU - Alexandre, Martine

AU - de Villalvilla, Alexander Diaz

AU - Kolodecik, Thomas R.

AU - Young, Lawrence H.

AU - Gorelick, Fred S.

AU - Thrower, Edwin C.

PY - 2012/9/15

Y1 - 2012/9/15

N2 - The premature activation of digestive enzyme zymogens in the pancreatic acinar cell is an important initiating event in acute pancreatitis. We have previously demonstrated that vacuolar ATPase (vATPase) activity is required for zymogen activation. Adenosine monophosphate-activated protein kinase (AMPK) regulates vATPase function in kidney and epididymal clear cells. To determine whether AMPK could affect pancreatitis responses, its effects were first examined in a cellular model of pancreatitis, cerulein-hyperstimulated (100 nM) pancreatic acini. This treatment caused a prominent increase in trypsin and chymotrypsin activities. Pretreatment with AICAR or metformin (AMPK activators) or compound C (an AMPK inhibitor) reduced or increased cerulein-induced zymogen activation, respectively. The association of the vATPase E subunit with membranes, a marker of its activation, tended to be inversely related to AMPK activity (assessed by AICAR and compound C treatments). Cerulein treatment did not change AMPK (- and -) levels but did lead to an increase in its activation (phosphorylation of Thr172) and induced the time-dependent translocation of the enzyme to a Triton-insoluble compartment. Basal in vivo studies showed that AMPK was widely distributed between membrane and soluble fractions generated by differential centrifugation. After cerulein hyperstimulation, AMPK levels selectively decreased in fractions containing the highest levels of active zymogens. These studies suggest that AMPK activity has a protective role in the pancreatic acinar cell that inhibits zymogen activation in the basal state, and this AMPK effect is reduced during pancreatitis. Therapies that prevent the selective reduction of AMPK in compartments that support zymogen activation could reduce injury during pancreatitis.

AB - The premature activation of digestive enzyme zymogens in the pancreatic acinar cell is an important initiating event in acute pancreatitis. We have previously demonstrated that vacuolar ATPase (vATPase) activity is required for zymogen activation. Adenosine monophosphate-activated protein kinase (AMPK) regulates vATPase function in kidney and epididymal clear cells. To determine whether AMPK could affect pancreatitis responses, its effects were first examined in a cellular model of pancreatitis, cerulein-hyperstimulated (100 nM) pancreatic acini. This treatment caused a prominent increase in trypsin and chymotrypsin activities. Pretreatment with AICAR or metformin (AMPK activators) or compound C (an AMPK inhibitor) reduced or increased cerulein-induced zymogen activation, respectively. The association of the vATPase E subunit with membranes, a marker of its activation, tended to be inversely related to AMPK activity (assessed by AICAR and compound C treatments). Cerulein treatment did not change AMPK (- and -) levels but did lead to an increase in its activation (phosphorylation of Thr172) and induced the time-dependent translocation of the enzyme to a Triton-insoluble compartment. Basal in vivo studies showed that AMPK was widely distributed between membrane and soluble fractions generated by differential centrifugation. After cerulein hyperstimulation, AMPK levels selectively decreased in fractions containing the highest levels of active zymogens. These studies suggest that AMPK activity has a protective role in the pancreatic acinar cell that inhibits zymogen activation in the basal state, and this AMPK effect is reduced during pancreatitis. Therapies that prevent the selective reduction of AMPK in compartments that support zymogen activation could reduce injury during pancreatitis.

KW - Pancreatic acini

KW - Vacuolar ATPase

UR - http://www.scopus.com/inward/record.url?scp=84866397772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866397772&partnerID=8YFLogxK

U2 - 10.1152/ajpgi.00082.2012

DO - 10.1152/ajpgi.00082.2012

M3 - Article

C2 - 22821946

AN - SCOPUS:84866397772

VL - 303

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 6

ER -